Literature DB >> 26241407

Determinants of Treatment-Resistant Depression: The Salience of Benzodiazepines.

Gordon B Parker1, Rebecca K Graham.   

Abstract

Treatment-resistant depression (TRD) lacks consensus regarding its definition, despite being common in clinical practice. This study was designed to identify factors contributing to TRD in patients diagnosed with a major depressive disorder. Patients were grouped into "low," "medium," and "high" treatment-resistant (TR) groups based on the number of medications that had been prescribed for their depression. We identified a number of factors linked to TRD. The high TR group was generally older, had a longer depressive episode duration, a higher number of comorbid medical and anxiety disorders, a lower education, and were less likely to be in full-time employment. They also reported less trait irritability and were more likely to view medication as being a contributor to their current depression. Some differences between non-melancholic and melancholic subsets were evident and point to the benefits in research on TRD analyzing the two diagnostic groups separately. The most striking finding was benzodiazepine use, which was significantly more common in the high TR group and within both the melancholic and non-melancholic subsets. Some potential explanations for this finding are offered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26241407     DOI: 10.1097/NMD.0000000000000348

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  8 in total

Review 1.  Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders.

Authors:  Thomas Prévot; Etienne Sibille
Journal:  Mol Psychiatry       Date:  2020-04-28       Impact factor: 15.992

2.  Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles.

Authors:  Thomas D Prevot; Guanguan Li; Aleksandra Vidojevic; Keith A Misquitta; Corey Fee; Anja Santrac; Daniel E Knutson; Michael Rajesh Stephen; Revathi Kodali; Nicolas M Zahn; Leggy A Arnold; Petra Scholze; Janet L Fisher; Bojan D Marković; Mounira Banasr; James M Cook; Miroslav Savic; Etienne Sibille
Journal:  Mol Neuropsychiatry       Date:  2019-01-23

3.  Treatment-resistant depression as risk factor for substance use disorders-a nation-wide register-based cohort study.

Authors:  Philip Brenner; Lena Brandt; Gang Li; Allitia DiBernardo; Robert Bodén; Johan Reutfors
Journal:  Addiction       Date:  2019-04-15       Impact factor: 6.526

4.  Frequent attenders in general medical practice in Italy: a preliminary report on clinical variables related to low functioning.

Authors:  Claudia Carmassi; Valerio Dell'Oste; Diana Ceresoli; Stefano Moscardini; Enrico Bianchi; Roberto Landi; Gabriele Massimetti; Cristiana Nisita; Liliana Dell'Osso
Journal:  Neuropsychiatr Dis Treat       Date:  2018-12-24       Impact factor: 2.570

5.  Prevalence of and pathways to benzodiazepine use in Brazil: the role of depression, sleep, and sedentary lifestyle.

Authors:  Clarice S Madruga; Thales L Paim; Hamer N Palhares; Andre C Miguel; Luciana T S Massaro; Raul Caetano; Ronaldo R Laranjeira
Journal:  Braz J Psychiatry       Date:  2018-10-11       Impact factor: 2.697

6.  Beyond Prescriptions Monitoring Programs: The Importance of Having the Conversation about Benzodiazepine Use.

Authors:  Erin Oldenhof; Jane Anderson-Wurf; Kate Hall; Petra K Staiger
Journal:  J Clin Med       Date:  2019-12-04       Impact factor: 4.241

Review 7.  Novel drug developmental strategies for treatment-resistant depression.

Authors:  Éva Borbély; Mária Simon; Eberhard Fuchs; Ove Wiborg; Boldizsár Czéh; Zsuzsanna Helyes
Journal:  Br J Pharmacol       Date:  2022-01-26       Impact factor: 9.473

8.  Substance use disorders and risk for treatment resistant depression: a population-based, nested case-control study.

Authors:  Philip Brenner; Lena Brandt; Gang Li; Allitia DiBernardo; Robert Bodén; Johan Reutfors
Journal:  Addiction       Date:  2019-12-16       Impact factor: 6.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.